Gain Therapeutics Receives Green Light for Parkinson’s Disease Trial
Australian regulators have given Gain Therapeutics (GANX) the thumbs up to proceed with the evaluation of GT-02287 in patients with Parkinson’s disease. This milestone has prompted Roth MKM to reaffirm its Buy rating and $7 price target on the company.
Positive Outcomes Expected from Phase 1b Study
According to the analyst, the Phase 1b study is likely to yield positive results, demonstrating the safety, preliminary biochemical efficacy, and tolerability of GT-02287. This optimism stems from the promising data gathered so far, which suggests that the treatment has the potential to make a significant impact on Parkinson’s disease patients.
Roth MKM’s Bullish Stance
Roth MKM’s confidence in Gain Therapeutics is rooted in the company’s innovative approach to addressing Parkinson’s disease. The analyst believes that GT-02287 has the potential to revolutionize the treatment landscape, making it an attractive investment opportunity.
Stay Ahead of the Curve with Expert Insights
Gain access to the latest stock recommendations from top Wall Street analysts, all in one convenient location. The Smart Investor Newsletter provides weekly expert stock picks, empowering you to make informed investment decisions. Try Now>>
Leave a Reply